Clinical Trial Search

Primary: Hearing Aid Use Measured Using In-situ Glasgow Hearing Aid Benefit Profile (EMA-GHABP-Use) — 4.4; 4.1; 3.8; 4.5 score on a scale

Primary: Number of Participants Who Did HIV Testing — 36; 9 Participants

Primary: Number of TH Clients Who Received HIV Testing — 57; 250 Participants — p=<0.001

Primary: Abbreviated Profile of Hearing Aid Benefit (APHAB) — 30.1; 21.4 score on a scale (1-99)

Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…

Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml

Primary: The Proportion of Young Men Who Have Sex With Men (YMSM) Who Test Positive for HIV at Enrollment — 70; 28; 280 Participants

Primary: Mean Score Change in Total HIV Stigma Scale — 47.48; 47.89; 44.60; 47.32 units on a scale — p=0.083

Primary: Point Prevalence Tobacco Abstinence — 25; 11 Participants

Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits

Primary: Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS) — 90.3; 90.0; 83.9; 90.0 percentage of taken doses — p=0.95

Primary: Death — 0 Participants

Primary: Adherence Rate — 20; 17 Participants — p=0.29

Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51

Primary: Baseline HIV DNA Reservoir: Total HIV DNA — 3.83; 3.67; 3.40 Log10 HIV DNA copies/10^6 CD4 T cells — p=0.048